Search This Blog

Friday, January 11, 2019

Knight in-licenses Puma Bio’s Nerlynx in Canada


Puma Biotechnology grants an exclusive license to Knight Therapeutics to commercialize breast cancer med NERLYNX (neratinib) in Canada.
Knight will be responsible for regulatory filings.
Puma will receive upfront and milestone payments of up to $7.2M, as well as double digit royalties on net sales.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)